Raghunandan R. Sagi
Known title: See RemarksCIK: 0002023890
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Carter's Stock Faces Slip and Lowered Price Target. Recent coverage notes that Carter's shares fell sharply, prompting a price target reduction to $30 by Wells Fargo. Analysts highlighted warning signs in the Russell 2000 and described the stock as potentially undervalued after a 60% decline. The company’s dividend yield of 4.4% and low P/E of 5.9 are cited as attractive income features, while the stock trades near its $37.59 support level.
Transaction History
| SIG | ▲ Buy | Grant | 47 | $0 | 8/21/2026 | View on chart |
| SIG | ▲ Buy | Grant | 48 | $0 | 5/22/2026 | View on chart |
| SIG | ▲ Buy | Grant | 5,564 | $0 | 3/24/2026 | View on chart |
| SIG | ▲ Buy | Grant | 18 | $0 | 2/20/2026 | View on chart |
| SIG | ▲ Buy | Grant | 5,405 | $0 | 1/12/2026 | View on chart |
| CRI | ▼ Sell | Tax Withholding | 1,621 | $55K | 5/10/2025 | View on chart |
| CRI | ▲ Buy | Grant | 15,360 | $0 | 2/26/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Signet Shares Rise 8.4% Post-Earnings; Blue Nile Partners with Royal Asscher
Signet shares have climbed 8.4% since the last earnings report, moving against a broader market dip. The company also announced that its Blue Nile brand is partnering with Royal Asscher, a move that may strengthen its product lineup. With an average analyst target of $125.90, the stock remains well below that level, sitting near its 52-week high of $110.20.
Signet Shares Rise 8.4% Post-Earnings; Blue Nile Partners with Royal Asscher. Signet shares have climbed 8.4% since the last earnings report, moving against a broader market dip. The company also announced that its Blue Nile brand is partnering with Royal Asscher, a move that may strengthen its product lineup. With an average analyst target of $125.90, the stock remains well below that level, sitting near its 52-week high of $110.20.